| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5537469 | Vaccine | 2017 | 7 Pages |
Abstract
To consider implementing any changes to the current program, most participants would require more evidence regarding PCV10 cross-protection and effectiveness against OM. Decreasing vaccine price was cited as a positive outcome of funding both vaccines.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Melissa Berman, Eve Dubé, Caroline Quach,